A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Oct 31, 2019

New England Journal of Medicine Publishes Results from Astellas’ Phase 3 ADMIRAL Trial of XOSPATA® (gilteritinib) in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia1

- Results were published online and in the October 31 print edition of the Journal -

TOKYO, October 31, 2019 - The New England Journal of Medicine published detailed results from the Phase 3 ADMIRAL trial, which found that Astellas Pharma Inc.’s (TSE: 4503, President and CEO:...

Read more about New England Journal of Medicine Publishes Results from Astellas’ Phase 3 ADMIRAL Trial of XOSPATA® (gilteritinib) in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia1
Oct 28, 2019

U.S. FDA Grants Fast Track Designation to Astellas for the Development of ASP1128 for Patients at Risk for Acute Kidney Injury

TOKYO, October 28, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has granted...

Read more about U.S. FDA Grants Fast Track Designation to Astellas for the Development of ASP1128 for Patients at Risk for Acute Kidney Injury
Oct 25, 2019

European Commission Approves Astellas’ XOSPATA™ (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

Approval follows accelerated assessment, orphan designation by European Medicines Agency

TOKYO, Oct. 25, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the European Commission (EC) has approved the oral...

Read more about European Commission Approves Astellas’ XOSPATA™ (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Oct 24, 2019

Astellas Announces Personnel Changes

Astellas Announces Personnel Changes

Read more about Astellas Announces Personnel Changes
Oct 18, 2019

Annual Report 2019 is now available.

To enable deeper stakeholder understanding of Astellas' efforts to continue to create value for sustainable growth, we have published the annual report as an integrated report. In order to provide...

Read more about Annual Report 2019 is now available.
Oct 15, 2019

Astellas Transfers Three Products in Asia Region to Daiichi Sankyo

TOKYO, October 15, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that subsidiaries of Astellas will transfer their marketing...

Read more about Astellas Transfers Three Products in Asia Region to Daiichi Sankyo
Oct 2, 2019

Astellas Commits Nearly $13 Million to Fund Boston-area Start-Up Innovation in Cell and Gene Therapy - Financial support for LabCentral Incubators builds on Astellas’ $1 Billion+ investment in Boston’s Life Science Community -

TOKYO, October 1 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced it will invest nearly $13 million into two innovation incubators...

Read more about Astellas Commits Nearly $13 Million to Fund Boston-area Start-Up Innovation in Cell and Gene Therapy - Financial support for LabCentral Incubators builds on Astellas’ $1 Billion+ investment in Boston’s Life Science Community -
Sep 30, 2019

Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer

- Study Met Outcomes for Safety and 71 Percent of Patients with Locally Advanced or Metastatic Urothelial (Bladder) Cancer Had a Confirmed Response -

TOKYO and BOTHELL, Wash., September 28, 2019– Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced...

Read more about Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer
Sep 24, 2019

Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

If approved by the European Commission, gilteritinib would represent one of the few advances in Europe for AML over the past 40 years1

TOKYO, Sept. 20, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the Committee for Medicinal Products for Human Use (CHMP)...

Read more about Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Sep 20, 2019

Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

TOKYO and San Francisco, September 20, 2019- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: James A...

Read more about Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts